SG11201907725SA - Tri-cycle compound and applications thereof - Google Patents
Tri-cycle compound and applications thereofInfo
- Publication number
- SG11201907725SA SG11201907725SA SG11201907725SA SG11201907725SA SG11201907725SA SG 11201907725S A SG11201907725S A SG 11201907725SA SG 11201907725S A SG11201907725S A SG 11201907725SA SG 11201907725S A SG11201907725S A SG 11201907725SA SG 11201907725S A SG11201907725S A SG 11201907725SA
- Authority
- SG
- Singapore
- Prior art keywords
- applications
- tri
- cycle compound
- compound
- cycle
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Disclosed in the present invention are a compound represented by formula (I), a tautomer thereof or a pharmaceutically acceptable salt, and applications thereof in the preparation of drugs for treating HBV-related diseases.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710100309 | 2017-02-23 | ||
| CN201710648155 | 2017-08-01 | ||
| CN201810008592 | 2018-01-04 | ||
| PCT/CN2018/075995 WO2018153285A1 (en) | 2017-02-23 | 2018-02-09 | Tri-cycle compound and applications thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201907725SA true SG11201907725SA (en) | 2019-09-27 |
Family
ID=63253508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201907725SA SG11201907725SA (en) | 2017-02-23 | 2018-02-09 | Tri-cycle compound and applications thereof |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11053260B2 (en) |
| EP (1) | EP3587420B1 (en) |
| JP (1) | JP6764039B2 (en) |
| KR (1) | KR102085497B1 (en) |
| CN (1) | CN109071544B (en) |
| AU (1) | AU2018223435B2 (en) |
| BR (1) | BR112019017603A2 (en) |
| CA (1) | CA3054324C (en) |
| DK (1) | DK3587420T3 (en) |
| ES (1) | ES2874656T3 (en) |
| HU (1) | HUE054822T2 (en) |
| IL (1) | IL268827A (en) |
| LT (1) | LT3587420T (en) |
| MX (1) | MX2019010042A (en) |
| MY (1) | MY175445A (en) |
| PH (1) | PH12019501955A1 (en) |
| PL (1) | PL3587420T3 (en) |
| PT (1) | PT3587420T (en) |
| RS (1) | RS61913B1 (en) |
| SG (1) | SG11201907725SA (en) |
| SI (1) | SI3587420T1 (en) |
| WO (1) | WO2018153285A1 (en) |
| ZA (1) | ZA201906135B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112334137A (en) * | 2018-05-03 | 2021-02-05 | 埃默里大学 | Orphan nuclear receptor modulators for NASH and other metabolic disorders |
| JP7118354B2 (en) | 2018-08-23 | 2022-08-16 | 福建▲広▼生中霖生物科技有限公司 | Crystal forms of tricyclic compounds and uses thereof |
| CN110172068A (en) * | 2019-06-05 | 2019-08-27 | 河南龙湖生物技术有限公司 | Benzothiazole compound with anti-tumor activity and its preparation method and application |
| US20220306648A1 (en) * | 2019-08-15 | 2022-09-29 | Fujian Akeylink Biotechnology Co., Ltd. | Preparation Method for Oxazepine Compound |
| WO2021213445A1 (en) * | 2020-04-22 | 2021-10-28 | 南京明德新药研发有限公司 | Sultam derivatives and application thereof |
| CN115515596A (en) * | 2020-05-15 | 2022-12-23 | 福建广生中霖生物科技有限公司 | Combination containing tricyclic compound and application thereof in preparing medicament for treating HBV |
| CN114456099A (en) * | 2022-02-21 | 2022-05-10 | 八叶草健康产业研究院(厦门)有限公司 | Preparation method of 4-chloropyrrole-2-carboxylic acid |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2443703C2 (en) | 2007-06-18 | 2012-02-27 | Саншайн Лейк Фарма Ко., Лтд | Bromophenyl substituted thiazolyl dihydropyrimidines |
| CN102060786A (en) | 2011-01-20 | 2011-05-18 | 天津大学 | 4-(substituted-1,3-diyne)-4-(trifluoromethyl)-3,4-dihydro substituted quinazoline-2-ketone compound as well as preparation method and application thereof |
| ES2640063T3 (en) | 2013-04-03 | 2017-10-31 | Janssen Sciences Ireland Uc | N-phenyl-carboxamide derivatives and their use as medicines for the treatment of hepatitis B |
| ES2777248T3 (en) | 2013-11-14 | 2020-08-04 | Novira Therapeutics Inc | Azepane derivatives and methods of treating hepatitis B infections |
| RS59430B1 (en) | 2014-03-13 | 2019-11-29 | Univ Indiana Res & Tech Corp | Hepatitis b core protein allosteric modulators |
| WO2015173164A1 (en) | 2014-05-13 | 2015-11-19 | F. Hoffmann-La Roche Ag | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection |
| TWI721016B (en) * | 2015-09-15 | 2021-03-11 | 美商艾森伯利生物科學公司 | Hepatitis b core protein modulators |
| EP3366684B1 (en) | 2015-10-23 | 2020-09-02 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| EP3512845A1 (en) | 2016-09-15 | 2019-07-24 | Assembly Biosciences, Inc. | Hepatitis b core protein modulators |
-
2018
- 2018-02-09 PL PL18757445T patent/PL3587420T3/en unknown
- 2018-02-09 WO PCT/CN2018/075995 patent/WO2018153285A1/en unknown
- 2018-02-09 JP JP2019557752A patent/JP6764039B2/en active Active
- 2018-02-09 LT LTEP18757445.4T patent/LT3587420T/en unknown
- 2018-02-09 EP EP18757445.4A patent/EP3587420B1/en active Active
- 2018-02-09 SI SI201830287T patent/SI3587420T1/en unknown
- 2018-02-09 RS RS20210671A patent/RS61913B1/en unknown
- 2018-02-09 SG SG11201907725SA patent/SG11201907725SA/en unknown
- 2018-02-09 BR BR112019017603-9A patent/BR112019017603A2/en active Search and Examination
- 2018-02-09 CA CA3054324A patent/CA3054324C/en active Active
- 2018-02-09 PT PT187574454T patent/PT3587420T/en unknown
- 2018-02-09 MY MYPI2019004841A patent/MY175445A/en unknown
- 2018-02-09 HU HUE18757445A patent/HUE054822T2/en unknown
- 2018-02-09 MX MX2019010042A patent/MX2019010042A/en unknown
- 2018-02-09 AU AU2018223435A patent/AU2018223435B2/en active Active
- 2018-02-09 US US16/488,244 patent/US11053260B2/en active Active
- 2018-02-09 KR KR1020197027723A patent/KR102085497B1/en active IP Right Grant
- 2018-02-09 ES ES18757445T patent/ES2874656T3/en active Active
- 2018-02-09 DK DK18757445.4T patent/DK3587420T3/en active
- 2018-02-09 CN CN201880001646.8A patent/CN109071544B/en active Active
-
2019
- 2019-08-21 IL IL26882719A patent/IL268827A/en active IP Right Grant
- 2019-08-23 PH PH12019501955A patent/PH12019501955A1/en unknown
- 2019-09-17 ZA ZA2019/06135A patent/ZA201906135B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN109071544B (en) | 2020-03-17 |
| CA3054324A1 (en) | 2018-08-30 |
| LT3587420T (en) | 2021-07-12 |
| EP3587420A1 (en) | 2020-01-01 |
| RS61913B1 (en) | 2021-06-30 |
| JP2020508342A (en) | 2020-03-19 |
| KR102085497B1 (en) | 2020-03-05 |
| PT3587420T (en) | 2021-06-04 |
| HUE054822T2 (en) | 2021-10-28 |
| AU2018223435A1 (en) | 2019-10-10 |
| MX2019010042A (en) | 2020-01-13 |
| DK3587420T3 (en) | 2021-06-07 |
| AU2018223435B2 (en) | 2020-12-24 |
| KR20190120300A (en) | 2019-10-23 |
| IL268827A (en) | 2019-11-03 |
| EP3587420B1 (en) | 2021-03-31 |
| SI3587420T1 (en) | 2021-09-30 |
| CA3054324C (en) | 2020-12-01 |
| ZA201906135B (en) | 2021-04-28 |
| US20200247819A1 (en) | 2020-08-06 |
| ES2874656T3 (en) | 2021-11-05 |
| US11053260B2 (en) | 2021-07-06 |
| CN109071544A (en) | 2018-12-21 |
| JP6764039B2 (en) | 2020-09-30 |
| PH12019501955A1 (en) | 2020-07-06 |
| WO2018153285A1 (en) | 2018-08-30 |
| PL3587420T3 (en) | 2021-10-11 |
| BR112019017603A2 (en) | 2020-03-24 |
| EP3587420A4 (en) | 2020-02-19 |
| MY175445A (en) | 2020-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018550120A1 (en) | Steroid derivative fxr agonist | |
| PH12019501955A1 (en) | Tri-cycle compound and applications thereof | |
| PH12019501688A1 (en) | Pyridine derivative as ask1 inhibitor and preparation method and use thereof | |
| ZA202202097B (en) | Amino pyrimidine ssao inhibitors | |
| SA520411524B1 (en) | Bisamide sarcomere activating compounds and uses thereof | |
| PH12019500480A1 (en) | Pyridine compound | |
| SA519402288B1 (en) | Pyrimidine compound and pharmaceutical use thereof | |
| MY194468A (en) | Oxy-fluoropiperidine derivatives as kinase inhhiitor | |
| MY194116A (en) | Pharmaceutical compounds | |
| MX2019006721A (en) | Treatment for primary biliary cholangitis. | |
| PH12016502246B1 (en) | Carboxamide derivatives | |
| TN2016000491A1 (en) | Carboxamide derivatives. | |
| MX2019010108A (en) | Azetidine derivative. | |
| PH12017501955A1 (en) | Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease | |
| EA201991910A1 (en) | TRICYCLIC CONNECTION AND WAYS OF ITS APPLICATION | |
| EA038580B9 (en) | Steroid derivative fxr agonist | |
| PH12016502247A1 (en) | Carboxamide derivatives |